Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study - Gupta, V; Kosiorek, H; Mead, A; Klisovic, R; Galvin, J; Berenzon, D; Yacoub, A; Viswabandya, A; Mesa, R; Goldberg, J; Price, L; Salama, M; et al. (Biology of Blood and Marrow Transplantation, 2018)